Alfonso Aguarón, Policy Officer for Lung Cancer Europe participated in the Week of Clinical Trials organised by EUPATI España

Lung Cancer Europe shared on LinkedIn:

“Last week, Alfonso Aguarón, Policy Officer for Lung Cancer Europe (LuCE), participated in the Week of Clinical Trials organised by EUPATI España. He took part in a roundtable discussion focusing on the new EU Health Technology Assessment (HTA) regulation and its impact on LuCE and the people they represent, specifically those affected by lung cancer.

The new HTA regulation, set to be implemented within the EU starting January 2025, aims to address unmet medical needs by introducing Joint Clinical Assessments (JCA) where new treatments are evaluated against existing alternatives. This regulation is expected to accelerate access to new medications, harmonise evaluation processes across EU member states, and emphasise the importance of considering patient perspectives.

For LuCE, this regulation means quicker access to innovative treatments for lung cancer patients, ensuring that they benefit from the latest medical advancements without undue delays. It also ensures that patient needs and experiences are central to the evaluation process, improving overall healthcare outcomes.

The event highlighted the importance of collaborative efforts among various stakeholders, including patient organisations, scientific societies, and industry representatives, in improving healthcare outcomes for lung cancer patients. LuCE is optimistic about the positive impact these regulatory changes will have on their community and remains dedicated to advocating for faster access to life-saving treatments.”

Source: Lung Cancer Europe/LinkedIn